Dyspnea, respiratory function and sputum profile in asthmatic patients during exacerbations  by ROSI, E. et al.
Vol.96 (2002) 745^750Dyspnea, respiratory function and sputumpro¢le in
asthmatic patients during exacerbations
E.ROSI*, B.LANINIw,M.C.RONCHI*, I.ROMAGNOLIw, L. STENDARDIw, R.BIANCHIw,
R. ZONEFRATI*, R.DURANTI* AND G. SCANO*,w
*Section of Immunology and Respiratory Diseases,Department of Internal Medicine,University of Florence, Italy and
wFondazione Don C.Gnocchi IRCCS Pozzolatico, Florence, Italy
Abstract Dyspnea is oftenused as amarkerof asthma severity although awide variation in dyspnea perception asso-
ciatedwith bronchoconstriction (PB) has been described in asthmatic patients.Ourhypothesis is thatchanges of airway
inflammation, airway narrowing and hyperinflationmay account for a part of the variability of breathlessness in sponta-
neous asthma attack.In asthmatic patientswith exacerbation ofthe disease, we evaluatedrespiratory function, dyspnea
(using visual Analogue ScaleFVAS) and peakexpiratory flow (PEF) values and variability (amplitude % mean), and spu-
tumcellular and biochemical profile before (day I) and after (day II) therapy with i.v. corticosteroids and inhaled b2-ago-
nists, as appropriate.By day II, forced expiratory volume in 1s (FEV1), inspiratory capacity (IC), PEF or VAS values and
variability, sputumeosinophils and eosinophilic cationic protein (ECP) hadimproved.Improvementofdyspnea expressed
as a decrease inVAS andreductioninvariabilityofdyspnea sensation significantlycorrelatedwith increase in FEV1 %pre-
dicted value (%pv) (P=0.03; r=0.72 and P=0.02; r=0.74, respectively).No significant correlationwas found between IC
and VAS either in absolute values or as changes from days I and II, nor between sputum outcomes and PEF or VAS,
regardless of how theyweremeasured.We conclude that in acute asthmatic patients, dyspneameasurement, functional
measurements and sputum analysis may be useful in monitoring disease activity, response to therapy and can provide
different information onthe state of the disease.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1343, available online athttp://www.idealibrary.comon
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Dyspnea, a major symptom of asthma, is often used
as a marker of disease severity and monitoring
of dyspnea is being recommended in self-management
plans for asthma (1).Nonetheless, awidevariation indys-
pnea perception associated with bronchoconstriction
(PB) has been described in asthmatic patients, and a sig-
ni¢cant percentage of asthmatics has been demon-
strated to have a low PB (2,3), these patients being
subject to delay the assumption for rescue treatment.
The in£uence of clinical, functional, psychological, and
pathological factors has been advocated to explain the
wide variation in PB among asthmatic subjects (4^6).
The number of factors involved is PB also explain the dis-
crepancies in terms of the relationship between changes
in dyspnea and function data reported in treating severeReceived13 February 2002, accepted in revised form 27 February 2002.
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son et al. (8) reported on independence of symptoms,
treatment regimen and airway function. Noseda et al.
(9) maintained that the reduction in dyspnea could not
be ascribed to an improvement of forced expiratory vo-
lume in 1s (FEV1) after a spontaneous acute asthma at-
tack.
Nonetheless, in evaluating the factors involved in
breathlessness during acute asthma exacerbation, the
following should be considered: (i) the reduced expira-
tory £ow is only one of themanymechanisms that occur
during an asthma attacks (10,11), (ii) dynamic lung
hyperin£ation (DH) contributes importantly to acute
breathlessness in asthma for a given level of bronchocon-
striction (10).
Our hypothesis is that changes in DH along with
changes in airway in£ammation and narrowing contri-
bute to explain a part of the variability of PB during re-
mission of spontaneous asthma attack. To validate this
hypothesis, we carried out the present study in patients
with exacerbated asthma before and after a short
course of corticosteriod treatment.
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We studied12 consecutive patients, aged 27^62, with ex-
acerbation of asthma.The diagnosis of chronic bronchial
asthma had been previously established according to
NHLBI (1) on the basis of history of episodes of dyspnea
withwheezing andbronchial hyperresponsiveness tohis-
tamine (provocative concentration of histamine causing
20% fall in FEV1FPC20 FEV1Fo8mg/ml). A previous
diagnosis of atopy was established on the basis of skin-
prick allergy tests with a battery of common aeroaller-
gen extracts. In 7 of the12 patients, skin-prick tests were
positive. An exacerbation of asthma was de¢ned by the
presence of dyspnea at rest with wheezing or nocturnal
symptoms disturbing sleep.
Lung function
Baseline pulmonary function testing was performed by
measuring static and dynamic lung volumes with a
water-sealed spirometer (Pulmonet Godart), as pre-
viously reported (12).The normal values for lungvolumes
are those proposed by the European Community for
Coal and Steel (13). Peak expiratory £ow (PEF) wasmea-
sured using mini-Wright peak £ow meters (Clement
Clarke International Ltd.,Harlow,U.K.).Patientswere in-
structedon the correctuse of themeter and the record-
ing form. After instruction, they performed the test
everymorninguponrising (morning PEF) andeverynight
(evening PEF) before assuming bronchodilator and re-
corded the highest value of three measurements on the
recording form (14).
Dyspneameasurement
Dyspnea was evaluated by the Visual Analogue Scale
(VAS) (15). Subjects were asked to rate their sensation
of dyspnea everymorning (morningVAS) and every night
(evening VAS) before administering bronchodilator, by
placing a verticalmark on a horizontal10 cm line labelled
‘‘no breathlessness at all’’ at the left end and ‘‘the most
breathlessness ever experienced’’ at the right end. The
dyspnea scorewas expressed as the distance of themark
to the left end of theVAS inmm (15).
Induction and analysis of sputum
Induction of sputum was performed according to the
method of Pin et al. (16). Brie£y,10min after fenoterol in-
halation (200mg), hypertonic saline was nebulized with
an ultrasonic nebulizer (Fisoneb; Fisons Corp., Roche-
ster, NY, U.S.A.) and was inhaled for 5-min periods for
up to 20min.The concentration of saline was increased
at intervals of 10min from 3 to 4%. FEV1was measured
every 5min during inhalation of hypertonic saline solu-
tion. The sputum induction procedure did not causetroublesome symptoms and the FEV1 did not decrease
by more than 20% in any subject. Every 5min subjects
were asked to try to cough sputum into a Petri dish and
to collect saliva in a separate container.Cytological ana-
lysis and eosinophilic cationic protein (ECP) measure-
ment were performed according to Ronchi et al. (17):
two or three plugs free of salivary contamination were
suspendedin dithiotreitol (DTT) solution (0.1%) and incu-
bated for 30min at 371C for slidemaking.Cellswere cen-
trifuged at1500 rpm for10min and then re-suspended in
saline.Three sputum slideswere then prepared for cyto-
logical examinationby cytocentrifugation.Cellswere air-
dried and stained with May^Grumwald^Giemsa stain.
Cell di¡erentials were determined by counting 200 non-
squamous cells on each sputum slide.The volume of the
remaining portion of sputum samples was determined
and an equal volume of DTT (0.1%) was added.The sam-
ples were mixed by vortex and incubated at 371C for
20min.The samples were then centrifuged at 1000g for
10min. The supernatants were aspirated and frozen at
701C for later ECP analysis. ECP was assessed by a
£uoroimmunoassay (CAP ECP FEIA Kabi Pharmacia,
Pharmacia Diagnostics AB,Uppsala, Sweden). Anti-ECP,
covalently coupled to immuno-CAP, reacted with the
ECP in the specimens. After washing, enzyme-labelled
antibodies against ECP were added to form a complex.
After incubation, unboundenzyme anti-ECPwaswashed
away and the bound complex was then incubated with a
developing agent. After stopping the reaction, the £uor-
escence of the eluate was measured in Fluoro-Count 96
(Kabi Pharmacia). The sensitivity of this technique is
o0.5mg/1. ECP was determined in duplicate.
Protocol
All patients were seen before any asthma treatment in
hospital (day I). Ten patients were admitted to hospital
for 3^5 days. Spirometry and sputum were performed
on the ¢rst day of observation (day I) and repeated 15
days later (day II). Patients were asked to measure PEF
and dyspnea sensation by using the VAS in the morning
and evening.Values obtained on days I and II were used
for the statistical analysis.
After obtaining respiratory function data and
collecting sputum, patients were treated with i.v. corti-
costeroids (methylprednisolone 0.5^1mg/kg/day) pro-
gressively tapered over 15 days and inhaled b2-agonists
as appropriate. From day I to day II, the patients also re-
ceived inhaled steroids (£uticasone or beclomethasone
by MDI (metered dose inhaler)).
Data analysis
PEF and VASvariability were assessed as within-day var-
iation (amplitude%mean) (18,19). Amplitude%mean
FIG 2. Forced expiratory volume in one second (FEV1) and in-
spiratorycapacity (IC) ondays Iand II.Meanvalueswithstandard
error (¢lled circles and bars) and individual data points (empty
symbols) are shown; pv: predictedvalue.
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lowest PEF [or VAS])/(mean value of either)100.
Statistical analysis
Mean values and standard errors of the mean (SE) were
calculated for all variables. Data obtained on days I and
II were compared using the Wilcoxon test for paired
samples.Regression analysis was performedusing Spear-
man’s correlation coe⁄cient. Po0.05 was considered
statistically signi¢cant. All statistical analyses were car-
ried out using the Statgraphics for Windows 5.0 package
(Manugistics, Rockville,MD,U.S.A.).
RESULTS
Dyspnea
On days I and II, morning VAS were signi¢cantly higher
than evening VAS (P=0.005 and 0.03, respectively) and
on day II, morning VAS was signi¢cantly lower than on
day I (P=0.003) (Fig.1).VAS variability in terms of amp%-
mean was signi¢cantly higher on day I than on day II
(P=0.02).
Pulmonary volumes and £ow
Onday I, FEV1was 61% (73.5) of the predicted value and
inspiratory capacity (IC)was 2.7 l (70.18).The FEV1% in-
crease from baseline after b2-agonist inhalation was 25
(73.15).On day II, FEV1was 88% (73.8) of the predicted
value and ICwas 3.2 l (70.26), both changes being signif-
icant (Po0.01) (Fig. 2).Both on days I and II, morning PEF
was signi¢cantly lower than evening PEF (P=0.003 and
0.03, respectively).On day II, both morning and evening
PEF were signi¢cantly higher than on day I (P=0.003 and
0.005, respectively) (rightpanel of Fig.1).PEF variability in
terms of amp%mean was signi¢cantly higher on day I
than on day II (P=0.02).FIG 1. Meanmorning (circles) and evening (squares) VAS and PEFoCell biology
On day I, sputum was obtained spontaneously while on
day II, it was obtained after induction with hypertonic
saline. Sputum eosinophils were above the normal range
(0^2.2%) in all patients (33%77.5) before treatment and
signi¢cantly (P=0.002) reduced (0.870.2) after treat-
ment. Sputum neutrophils were increased in eight pa-
tients but una¡ected by treatment: from 27%76.9 to
36%77.5 (P=NS). Compared to the normal range in our
laboratory (0^70mg/l) sputum ECP wasmarkedly higher
(2812mg/l71301) before treatment and signi¢cantly
decreased (351mg/l7166) (P=0.001) after treatment even
if in eight patients it remained above the normal range
(Fig. 3).
Correlations
The reduction in variability of dyspnea sensation mea-
sured as amp%VAS (amp%VAS measured on day
Iamp%VASmeasured on day II) signi¢cantly correlated
with increase in FEV1 %predicted value (%pv) (P=0.02;
r=0.74) and improvement of dyspnea expressed as de-
crease inVAS (DVAS: VAS measured in the morning on
day IVAS measured in the morning on day II) signi¢-
cantly correlated with increase in FEV1 (P=0.03; r=0.72)
(Fig. 4).No signi¢cant correlationwas found between ICn days I and II.Lines represent standard errors.
FIG 3. Sputum eosinophils (% total cell count), sputumneutrophils (% total cell count) and sputum ECP (mg/1) on days I and II.Mean
values with standard error (¢lled circles and bars) and individual data points (empty symbols) are shown. Dashed area represents
normalvalue range.
748 RESPIRATORYMEDICINEandVAS either in absolutevalues or as changes fromdays
I and II (Table1). PEF or VAS and their variability did not
relate to each other (Table1).
Finally, sputum outcome values did not signi¢cantly
correlatewith PEF orVASvalues, variability or lung func-
tion (Table1).
DISCUSSION
In this study, we found that in patients with asthma ex-
acerbation FEV1, IC, PEF and VAS signi¢cantly improved
with treatment while sputum eosinophils and sputum
ECP signi¢cantly decreased.Unlike FEV1, neither airway
in£ammation outcomes, nor PEF nor IC related to dys-
pnea.
Dyspnea, one of the main symptoms of asthma, is of-
ten used to assess the severity of the disease. Self-man-
agement plans for asthmatic patients recommend the
monitoring of dyspnea (1). In order to measure dyspnea
sensation during and after an exacerbation of asthma,
we chose to administer VAS to our patients at di¡erent
times of the day.VAS has been adopted in asthma for the
subjective measurement of dyspnea and provides a reli-
able and sensitivemeasure (20,21).
Diurnal variability of VAS (amp%mean) has been used
to measure variability in dyspnea sensation (15). Our
study, which shows a signi¢cantreduction in absolute va-
lue and variability of VAS, supports this application of
VAS.
Several lines of evidence indicate that eosinophilic air-
way in£ammation may have either a positive or a detri-
mental e¡ect on perception of bronchoconstriction
dependingonwhether patients are ICSna|«ve or ICS trea-
ted (4^6). It is well known that in£ammation in asthma is
mostly characterized by the presence and activation of
eosinophils (22,23) and that the release of eosinophil ca-
tionic proteins is responsible for the airway damage. To
assess the in£ammatory response of the bronchial mu-cosa, we performed cytological and biochemical (ECP)
analyses of sputum which have been recently proposed
as a non-invasivemethod to investigate airway in£amma-
tion in stable asthma (16,17,24).More recently, the exam-
ination of sputumhas also been proposed as a valid guide
for monitoring asthma treatment after a severe exacer-
bation (25). In our study, sputum eosinophils and ECP,
but not neutrophils, were markedly reduced at the end
of observation.These results are in linewith the ¢ndings
of Pizzichinietal. (25)who found a reduction inboth spu-
tumeosinophils and sputumECP in acute asthma treated
with prednisone.However, wewere not able to observe
any signi¢cant correlation among airway in£ammation
outcomes, and dyspnea measurements and their respec-
tive improvements. This may be explained with the de-
monstration that in acute asthma clinical and functional
measurement do not accurately re£ect the airway in-
£ammatory response to anti-in£ammatory therapy
(25,26).
Our results showing that short-term change in FEV1
predicted short-term changes in breathlessness are not
in line with the results by Janson et al. (8). Di¡erent ex-
perimental models and severity of airway obstruction
mayexplain the di¡erentresults.Nonetheless, it has also
been shown thathyperin£ationpartly accounts for inter-
subject variability in breathlessness for a given level of
FEV1 decrease in methacholine-induced asthma and it is
the strongest predictor of symptom recovery (10).
Although not precisely de¢ned in its mechanisms, DH is
associated with important negative consequenes: (i) in-
crease inmechanical load for the respiratorymuscles al-
ready burdened with substantial resistive work (27,28);
(ii) attendant inspiratory threshold load at the beginning
of inspiration in somepatients (27,28); (iii) decreased abil-
ity of inspiratorymuscles to pressure generation (29) de-
spite the increased respiratory drive (30). All these
factors play an important role in breathlessness (31).
Despite the signi¢cant increase in ICparalleled the sig-
ni¢cant decrease inVAS, the two variables did not relate
TABLE 1. Correlations among lung function, PEF and dyspnea variability and sputum cellular and biochemical pro¢le in asth-
matic patients duringacute asthma
1 2 3 4 5
1 PEF (amp%mean) day I F F F F F
2 FEV1day I 0.68* F F F F
3 ICday I 0.32 0.34 F F F
4 VAS (amp%mean) day I 0.06 0.07 0.15 F F
5 Eosinophils day I 0.29 0.36 0.40 0.30 F
6 ECP day I 0.01 0.1 0.31 0.25 0.61*
*Po0.05;PEF: peakexpiratory £ow;FEV1: forcedexpiratory volumeinone second;IC: inspiratorycapacity;VAS:Visual Ana-
logue Scale;ECP: eosinophilic cationic protein
FIG 4. Left panel: correlation between decrease inVAS variability (measured as amp%VAS on day Iamp%VAS on day II) and in-
creasein FEV1 (measuredas FEV1 (% pv) onday IIFEV1 (%pv) onday I).Rightpanel: correlationbetweendecreaseinVASmeasuredin
themorning (morningVASonday IImorningonday II) andincreasein FEV1 (measuredas FEV1 (%pv) onday IIFEV1 (% pv) onday I);
pv: predictedvalue.
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variability inVAS.What is the explanation for this? It has
longbeen shown that TLCdoes not change in airway ob-
struction of asthma (32) so that ICrepresents themirror
image of end expiratory lung volume (EELV): the lower
the former, the higher the latter during an asthma at-
tack. Assuming similar reciprocal change in our study,
we should conclude that change in EELV was not an im-
portant contributor to breathlessness. One reason for
this may be that decrease in IC was minimal (see Fig. 2)
such as not to in£uencepressureproduction and thereby
inspiratory muscle e¡ort.The discrepancy between our
study and that of Lougheed et al. (10) showing that FRC
(functional residual capacity) contributed to dyspnea
after adjustment for FEV1 decrease with methacholine,
likely depends on the following: (i) a smaller increase in
EELV in our study and (ii) the di¡erent experimental
model and the di¡erent experiences su¡ered during an
asthma attack vs induced bronchoconstriction.
Increased spontaneous variation in airway caliber has
oftenbeendescribed as a characteristic hallmarkof asth-
ma (33,34) and themeasurement of PEF has been univer-sally accepted as a simple and valuable clinical tool for
assessing the degree of airway obstruction (35). PEF
measurements are now recommended in the guidelines
for diagnosis and management of asthma and diurnal
PEF variability is consideredone of the indicators of asth-
ma severity (1). Nonetheless, in the present study,
improvement in PEF values and a reduction in its variabil-
ity after corticosteroid therapydidnotprovide any infor-
mation about the symptom of breathlessness.
In conclusion, we found that in patients with acute
asthma, nor dynamic lung hyperin£ation nor markers of
in£ammation such as sputum cellular and biochemical
pro¢le are related to dyspnea sensation. Thus, in this
condition, PEF, dyspnea measurements, lung function
and sputum outcomesmay all provide independent infor-
mation on the state of the disease.
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